M

Madrigal Pharmaceuticals
D

MDGL

327.41
USD
-7.67
(-2.29%)
مفتوح الان
حجم التداول
556
الربح لكل سهم
-12
العائد الربحي
-
P/E
-15
حجم السوق
7,238,787,849
أصول ذات صلة
E
EXEL
-0.170
(-0.46%)
36.900 USD
INSM
INSM
-0.370
(-0.50%)
73.060 USD
K
KPTI
0.52000
(14.77%)
4.04000 USD
المزيد
الأخبار المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.